Anixa Biosciences (NASDAQ:ANIX) Research Coverage Started at Maxim Group

Maxim Group assumed coverage on shares of Anixa Biosciences (NASDAQ:ANIX) in a research note released on Friday, Marketbeat reports. The firm issued a buy rating and a $10.00 price objective on the stock.

A number of other brokerages also recently commented on ANIX. HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of Anixa Biosciences in a research note on Tuesday, February 18th. D. Boral Capital restated a “buy” rating and issued a $10.00 target price on shares of Anixa Biosciences in a research note on Wednesday, January 22nd.

Anixa Biosciences Price Performance

Shares of NASDAQ ANIX opened at $3.16 on Friday. The business’s 50-day moving average price is $2.89 and its two-hundred day moving average price is $3.01. Anixa Biosciences has a one year low of $2.07 and a one year high of $4.20. The company has a market capitalization of $101.74 million, a P/E ratio of -8.10 and a beta of 0.86.

Anixa Biosciences (NASDAQ:ANIX) last issued its earnings results on Tuesday, March 11th. The company reported ($0.10) EPS for the quarter, meeting analysts’ consensus estimates of ($0.10). On average, equities analysts anticipate that Anixa Biosciences will post -0.41 EPS for the current year.

Insider Activity

In related news, CEO Amit Kumar acquired 43,000 shares of the stock in a transaction dated Wednesday, January 15th. The shares were acquired at an average price of $2.23 per share, with a total value of $95,890.00. Following the acquisition, the chief executive officer now owns 559,925 shares in the company, valued at approximately $1,248,632.75. The trade was a 8.32 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Lewis H. Titterton, Jr. acquired 10,000 shares of the stock in a transaction dated Friday, January 17th. The shares were bought at an average cost of $2.57 per share, for a total transaction of $25,700.00. Following the acquisition, the director now owns 922,334 shares in the company, valued at $2,370,398.38. The trade was a 1.10 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 75,289 shares of company stock valued at $177,021. Insiders own 25.30% of the company’s stock.

Institutional Trading of Anixa Biosciences

Several hedge funds have recently added to or reduced their stakes in the business. Millennium Management LLC bought a new stake in Anixa Biosciences during the 4th quarter valued at approximately $26,000. Focus Partners Wealth bought a new stake in Anixa Biosciences during the 4th quarter valued at approximately $162,000. Jane Street Group LLC bought a new stake in Anixa Biosciences during the 4th quarter valued at approximately $67,000. Renaissance Technologies LLC boosted its stake in Anixa Biosciences by 36.5% during the 4th quarter. Renaissance Technologies LLC now owns 14,573 shares of the company’s stock valued at $34,000 after purchasing an additional 3,900 shares during the period. Finally, LPL Financial LLC boosted its stake in Anixa Biosciences by 37.2% during the 4th quarter. LPL Financial LLC now owns 42,937 shares of the company’s stock valued at $100,000 after purchasing an additional 11,633 shares during the period. Institutional investors own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.